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Abstract 
Psychotic major depression is an under researched and under identified disorder. We highlight 
the major challenges both in clinical practice and in conducting research with people with this 
disorder. We also suggest which major issues need addressing to move treatment and knowledge 
of this disorder forward.  
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ICD–101 classifies a depressive disorder with the presence of delusions, hallucinations or 
depressive stupor as a severe depressive episode with psychotic symptoms: also known as 
psychotic major depression (PMD). Hallucinations and delusions may be mood-congruent 
(consistent with depressive themes, e.g. guilt, death, nihilism), or mood-incongruent (not 
consistent with depressive themes, e.g. persecution, delusions of control, thought insertion). Both 
DSM-IV-TR2 and DSM-53 have a similar definition.  
 
The point prevalence of PMD in the general population has been estimated at around 0.4% 
(4/1000)4,5 compared to around 0.46% (4.6/1000) for schizophrenia.6 Some research suggests 
that PMD may have a similar7 or higher8 incidence compared to other psychotic disorders such 
as schizophrenia although other research challenges this and the discrepancy is likely to be due 
to methodological differences.9 
 
Few studies have investigated long-term outcomes in people with PMD. Those that have 
highlighted similar10 or increased11,12 risk of mortality compared to people with schizophrenia 
and increased mortality compared to people with bipolar disorder.13-15 Further, research has 
found that PMD cases have an increase in suicide attempts compared to schizophrenia and 
bipolar disorder16 as well as an increased risk of completed suicide compared to 
schizophrenia17,18 and bipolar disorder.13,14,15,18 A more recent study conducted over 10 years 
reported that people with PMD had better social and service use outcomes compared to people 
with schizophrenia, but were more likely to attempt suicide or self-harm.19  
 
This severe clinical picture highlights the need for prompt identification and treatment of PMD. 
However, this is exactly where there is a lack of knowledge and highlights an urgent need for 
more research.  
 
Identification problems 
The National Collaborating Centre for Mental Health20 stated that PMD is often not diagnosed 
accurately because the psychosis may be “subtle, intermittent or concealed”. Rothschild and 
Schatzberg21 state that PMD is often confused with NPMD and other psychotic disorders and 
emphasized that patients with PMD are unlike other patients with psychosis as they frequently 
recognise that their thinking processes are flawed, are embarrassed, and keep their unusual 
thoughts and feelings to themselves.  
 
The difficulties with identification of PMD cases has been demonstrated by Rothschild and 
colleagues22 who examined patient notes and found that out of the 130 diagnoses made for 66 
patients only 65% of diagnoses were correct. Moreover, none of the patients with an incorrect 
diagnosis were diagnosed with a psychotic disorder indicating it is the psychotic features rather 
than the depression which is being missed but also suggest it may not be that they are missing 
symptoms entirely but do not recognize them as delusional (guilt, poverty, persecution are 
common). This is clearly a problem in clinical practice as lack of identification will lead to 
inappropriate treatment and possibly allow symptoms to worsen.  
 
There have been multiple ways suggested to overcome this from ask the patient about any 
‘irrational worries’ as a way to illicit psychotic beliefs without labelling thoughts as such, thus 
making the patient more comfortable in disclosing,23 to asking permission to speak to the 
patient’s family to try to elicit any unusual thoughts, unusual experiences or paranoia,23 to using 
adapted assessment scales.24-26 However, the sensitivity and specificity of these have not been 
tested sufficiently.  
 
Regardless of which method is used, these methods could aid not just secondary mental health 
services to identify patients with PMD and therefore, treat accordingly, but could also be used in 
primary care with any patients presenting with depression to rule out PMD. 
 
Treatment gaps 
There is a lack of evidence based treatment options for PMD. Crebbin et al.10 state that people 
with PMD are a largely under researched group. This lack of research on PMD is demonstrated by 
National Institute for Health and Clinical Excellence (NICE) guidelines27 in which the only 
paragraph on the treatment of PMD is:  
 
“1.10.3.1 For people who have depression with psychotic symptoms, consider augmenting the 
current treatment plan with antipsychotic medication (although the optimum dose and duration of 
treatment are unknown)”. 
 
The update in 201020 added a clinical summary that stated that there was no good quality 
evidence for pharmacological treatments of PMD as there are practical problems in recruiting 
sufficient numbers of patients with PMD and therefore, clinicians should consider lower levels of 
evidence, but the guidelines do not indicate what.  
 
Parker et al.28 conducted a meta-analysis of studies comparing combination antidepressant-
antipsychotic therapies versus electroconvulsive therapy (ECT) versus antidepressant alone or 
antipsychotic alone for treating people with PMD. The authors reported a trend for ECT being 
more effective compared with combination drug therapy and significantly more effective 
compared to tricyclic drugs alone. Antidepressant-antipsychotic combinations were more 
effective than antipsychotic or antidepressant alone but not significantly so. A more recent study 
reported a 95% remission rate in people with PMD following bilateral ECT29 and another 
reported that psychotic features in depressed patients were associated with remission (OR=7.18, 
p=.032) following treatment with ultrabrief right unilateral ECT.30 However, neither of these 
studies compared ECT to antidepressant/antipsychotic medication thus limiting the conclusions 
about the best line of treatment.  
 
Two decades on and the evidence base has progressed little. Farahani and Correll31 conducted a 
systematic review and meta-analysis of trials comparing antidepressant versus antipsychotic 
versus combination treatment for people with PMD. They concluded that antidepressant-
antipsychotic co-treatment was superior to both monotherapies but could not comment on 
specific combinations. Leadholm et al.32 reviewed nine international treatment guidelines and 
found that they had contrasting opinions on the optimal treatment for PMD. Six suggested 
antidepressant-antipsychotic combination therapy and three recommend antidepressant 
monotherapy. Five recommend electroconvulsive therapy (ECT) to be equally as appropriate as 
medication as a first line treatment. In the latest guideline for treating depressive disorders from 
the British Association for Psychopharmacology,33 an unspecified combination of antidepressant 
with antipsychotic is advised over antidepressant or antipsychotic alone, with a recommendation 
to consider ECT. The only guideline to mention the use of psychological therapies in people with 
PMD is the Canadian Network for Mood and Anxiety Treatments Clinical Guidelines34 which states 
that “psychological therapies are not indicated” for people with PMD. 
 
Conducting research on effective and cost-effective treatments for PMD is clearly going to be 
difficult while we are still struggling to identify people with PMD. However, this is also 
compounded by the issue of diagnostic stability.  
 
Diagnostic issues 
Estimates of prospective diagnostic stability for PMD are wide ranging from 24-100%35-36 
compared to 50-100% for schizophrenia,37-38 around 40% for non-psychotic depression and 
around 35% for bipolar disorder.39 This wide variation in prospective consistency is likely due to 
the large amount of heterogeneity of the studies (i.e. different diagnostic tools, widely varying 
follow-up lengths, differing samples and differing quality). Cases recruited from non-first episode 
samples are effectively sampling prevalence cases in treatment, biasing the investigation towards 
those who are more unwell. If only studies based on an incidence sample are included,10,40-43 the 
prospective consistencies are 47-95% for PMD, compared with 73-96% for schizophrenia. 
However, these estimates were taken over 6 months to 10 years. As might be expected, the 
reliability of PMD as a diagnosis is directly linked the duration of follow-up with stability 
decreasing over time varying from 95% at 6 months to 48% at 10 years.10,40-43  
 
Diagnostic stability appears to be linked with age. A study on risk factors for conversion from 
PMD to bipolar disorder reported that as the age of onset increased, the chance of changing to 
bipolar decreased.44 Another examined on the progression from unipolar depression to 
schizophrenia and reported the strongest predictor of progression to schizophrenia included 
younger age.45 
 
The diagnostic instability of PMD has implications for all research on PMD. When studying 
aetiology of a disorder, incidence samples are thought to be preferred because prevalence 
samples bias results towards those who are more unwell. However, when diagnostic instability 
is high, incident diagnoses are likely to change and therefore the results may no longer apply. 
Similarly, any study using baseline diagnoses are likely to be undermined when diagnostic change 
is taken into account. 
 
This also raises the issue of what it means that PMD is diagnostically instability. It is beyond the 
scope of this article to review the evidence and hypotheses about the meaning of diagnostic 
instability in psychiatry, but is worth bearing in mind that diagnostic groupings are still a work 
in progress, and a major change in our categorisation of disorders could have major impacts on 
clinical decisions and research methodologies.  
 
Measurement of severity 
Measurement of severity of disorder is important as it allows monitoring of an individual and the 
progression of their disorder.46 However, most instruments have been designed to evaluate one 
aspect of the disorder in PMD, psychosis or depression, but not both. In 2014, the Psychotic 
Depression Assessment Scale (PDAS) was created to measure the severity of PMD.24 The scale 
was developed from relevant items from the 17-item Hamilton Depression Rating Scale and the 
Brief Psychiatric Rating Scale. The PDAS has shown clinical validity, responsiveness and 
unidimensionality in the measurement of PMD severity.24 The tool has been shown to be able to 
detect statistically significant differences in treatment effects in studies of medication efficacy in 
people with PMD.25 Additionally, the PDAS may be able to be used as a PMD detection tool among 
patients with depression.26, 47 
 
Where to go from here 
There are many questions that clinicians and researchers might ask about PMD that are not 
covered here such as whether PMD is a subtype of psychosis or depression, or a completely 
separate entity that needs a distinct diagnostic category.21,23,48-54 However, it is clear, that there 
are some major challenges in advancing our knowledge about PMD. The major questions for 
clinical practice are: how do we better identify PMD and what are the most effective and cost-
effective treatments. Current research challenges include the challenge of studying more 
representative samples, how to best identify people with PMD and how to improve diagnostic 
stability.  
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